Clinical Trial

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-02.
Trial Details
NCT Number NCT07454382
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Pfizer
Conditions Multiple Myeloma
Enrollment 26 participants
Start Date 2026-02-27
Primary Completion 2029-08-27 (estimated)
Study Completion 2029-08-27 (estimated)
Updated on ClinicalTrials.gov 2026-06-16